Actinium Pharmaceuticals Inc. reported positive preliminary data from the phase 2 trial of Actimab-A to treat patients with acute myeloid leukemia.
The ongoing study is being conducted in 13 patients with newly diagnosed acute myeloid leukemia, or AML, aged 60 and above and not able to tolerate induction chemotherapy.
According to the the initial data presented at the 59th American Society of Hematology Annual Meeting, 69% of patients saw a reduction in their disease. The patients also had a median reduction in bone marrow blasts of 98%.
There were minimal extramedullary toxicities recorded, with only pneumonia and septic shock observed in more than one patient in the trial. There was no evidence of veno-occlusive disease of any grade in any of the patients.
Veno-occlusive disease is a potentially fatal complication of the liver that can prevent a patient from having a stem cell transplant.